• Sridhar Rathinam, Antony Bleetman, David W Quinn, and Richard S Steyn.
• Regional Department of Thoracic Surgery, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK.
• Emerg Med J. 2011 Sep 1;28(9):750-3.

BackgroundThoraQuik is a device with a unique design incorporating an aspiration port and one-way valve controlled by a three-way tap, fit for purpose for the treatment of pneumothorax and pleural effusion. Its use, safety and efficacy were evaluated in a prospective observational trial.MethodsStage 1: The safety and ability of the device to penetrate the chest wall and the ease of use were evaluated in patients undergoing thoracoscopic procedures by introducing the device at a second port site under vision. Stage 2: The device was evaluated on patients with pneumothorax and pleural effusion. Clinical and radiological improvement were endpoints and operator feedback was evaluated.ResultsPhase 1: 10 patients (mean age: 48.5 years (18-76 years) six men) were studied between May 2005 and March 2007. Satisfactory penetration of the chest wall and safe entry in the pleural space was achieved. Phase 2: 20 patients (mean age: 59 years (24-81 years) 13 men) were recruited between May 2007 and May 2008. 10 patients presented with pneumothorax (tension pneumothorax, n=1) and 10 had pleural effusions. One patient withdrew consent and another patient was withdrawn as there was no fluid on trial aspiration. Of the 18 who completed the study, 10/18 had partial and 7/18 patients had complete resolution with no change in one. The qualitative assessments of the ThoraQuik in terms of ease of use and utility were positive.ConclusionsThoraQuik achieves satisfactory penetration of the chest wall. It was safe and easy to use to manage pneumothoraces and pleural effusions.

22 keywords...

hide…